A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
The study will compare the efficacy and safety of entrectinib with crizotinib in participants
with advanced or metastatic ROS1 non-small cell lung cancer (NSCLC). The participants will
self-administer oral entrectinib or crizotinib as described in the protocol and local
prescribing information. Treatments will continue until progressive disease, unacceptable
toxicity, death, or withdrawal from the study, whichever occurs first.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.